行 业 及 产 业 电力设备/ 光伏设备 2026 年 02 月 10 日 爱旭股份与 Maxeon 达成专利许 研究支持 李冲 A0230524070001 lichong@swsresearch.com 联系人 李冲 A0230524070001 lichong@swsresearch.com 行 业 研 究 / 行 业 点 评 相关研究 证 券 研 究 报 告 证券分析师 马天一 A0230525040004 maty@swsresearch.com 李冲 A0230524070001 lichong@swsresearch.com 行业点评 ⚫ 事件：爱旭股份与 Maxeon 达成"5 年期 16.5 亿元"的 BC 专利许可，核 心条款为爱旭与 Maxeon 签署 BC 电池与组件专利许可，期限五年、总额 16.5 亿元，许可区域为全球（美国除外），性质为非独家授权，双方同步 撤回相关未决诉讼。该许可协议将推动光伏"反内卷"路径从价格自律转向 知识产权法治化。 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 博时基金 博时基金管理有限公司(researchreport@bos ...

Core Viewpoint - Chinese companies planning to go public are facing unprecedented compliance challenges due to systemic restructuring of global capital market access rules and a shift in regulatory focus from "formal compliance" to "substantive risk" penetration [3] Group 1: Capital Market Regulatory Trends - Nasdaq has significantly raised financial and liquidity thresholds for Chinese companies seeking to list, with a minimum IPO requirement set at $25 million and a public holding market value requirement increased from $5 million to $15 million [4] - The calculation of "non-restricted public share market value" has been tightened to combat inflated listings, compelling companies to issue sufficient new shares to create genuine market liquidity [4] - Regulatory logic has shifted from "checklist compliance" to "risk assessment," allowing Nasdaq to reject listing applications based on potential market manipulation risks, even if all formal requirements are met [5] Group 2: Compliance Risk Factors for IPO Companies - Companies must focus on four interrelated core risk factors: 1. Intellectual Property Risk: Questions regarding ownership clarity, potential disputes, and the robustness of the intellectual property portfolio [10] 2. Data Compliance and Cybersecurity Risk: Compliance with data protection laws and the legality of data processing activities, especially for tech companies [11] 3. Cross-Border Operations and Corporate Governance Risk: Concerns regarding the legality and stability of VIE structures and the independence of corporate governance [12] 4. Information Disclosure Consistency Risk: Any inconsistencies in disclosures can trigger regulatory scrutiny, necessitating coherent and well-supported information across all documents [14] Group 3: Compliance Management Framework - Companies are encouraged to adopt international standards such as GB/T 29490-2023 for intellectual property compliance management and ISO 37301:2021 for compliance management systems to enhance their governance capabilities [15][16] - The establishment of a robust compliance management system is essential for companies to demonstrate their governance maturity and long-term investment value [9] Group 4: Implementation Path for Compliance Management - The compliance management system should follow a "Plan-Do-Check-Act" (PDCA) cycle, typically taking 6-12 months to implement [19] - Key phases include strategic diagnosis and planning, system construction and documentation, system operation and internal auditing, and certification verification [20][24][26][30] - Third-party certification can enhance the credibility of compliance management claims and improve communication with regulatory bodies [31] Group 5: Future Implications - The evolving regulatory landscape necessitates a profound compliance revolution for Chinese companies, particularly in hard tech and cross-border operations, where the ability to construct and validate a forward-looking compliance framework will be critical for successful listings and future valuations [32]

Core Viewpoint - Chengdu Olin Biotechnology Co., Ltd. is facing a contract dispute involving two core vaccine products, leading to the freezing of some bank accounts, which has raised market concerns. The plaintiff claims a total of 19.2 million yuan in technical commissions and penalties, exceeding the company's net profit for the first half of 2025, highlighting potential risks in intellectual property compliance and information disclosure [1][4]. Group 1: Historical Cooperation and Disclosure Issues - The plaintiff asserts that a contract was signed in 2011, providing technical materials for specific vaccines, but no mention of this relationship was found in the company's IPO documentation from 2021, raising questions about the completeness of the IPO materials [5][6]. - The company emphasized its focus on independent research and collaboration with academic institutions in its prospectus, omitting the key technical provider, which could lead to regulatory scrutiny regarding compliance and potential omissions during the IPO process [5][6]. Group 2: Financial Impact of the Lawsuit - The frozen amount of 19.2 million yuan exceeds the company's net profit of 13.2 million yuan for the first half of 2025. Although the company claims the frozen accounts are not essential for operations, the liquidity pressure and financial risks cannot be overlooked [2][3]. - The two products involved in the lawsuit are projected to generate nearly 50 million yuan in revenue in 2024, with gross margins exceeding 76%, making them significant profit sources for the company. Any impact on production and sales due to the lawsuit could directly affect the company's performance [6][7]. Group 3: Legitimacy of Technology Sources - The company asserts that the products in question are legally marketed and compliant with regulations, claiming no rights defects. However, the plaintiff's claims challenge the legitimacy of the technology sources, which could jeopardize the company's rights and affect product qualifications and commercial sustainability if the court supports the plaintiff [7][8]. - The dispute reveals potential weaknesses in the company's early technology cooperation management, contract execution, and intellectual property compliance, which are critical for a technology-driven enterprise [7][8]. Group 4: Compliance and Transparency - The lawsuit, stemming from a contract signed 14 years ago, underscores the need for improved consistency in information disclosure and management of technology cooperation, as well as heightened awareness of legal risk prevention [3][8]. - In the context of stringent regulations and high compliance requirements in the pharmaceutical industry, companies must focus not only on product development and market expansion but also on strengthening internal controls and compliance measures to maintain transparency and stability in the eyes of investors and the market [3][8].